|
gptkbp:instance_of
|
gptkb:legal_case
|
|
gptkbp:addressed
|
unmet medical needs
|
|
gptkbp:aims_to
|
gptkb:sacubitril/valsartan
|
|
gptkbp:applies_to
|
chronic heart failure
|
|
gptkbp:business_model
|
gptkb:battle
|
|
gptkbp:can_lead_to
|
gptkb:Dr._John_Doe
|
|
gptkbp:collaborated_with
|
academic institutions
|
|
gptkbp:collaborations
|
international research collaboration
|
|
gptkbp:completed
|
gptkb:2021
|
|
gptkbp:conducted
|
multiple countries
clinical research organizations
|
|
gptkbp:controls
|
placebo
|
|
gptkbp:criteria
|
severe renal impairment
|
|
gptkbp:data_usage
|
meta-analyses
|
|
gptkbp:distribution
|
gptkb:battle
|
|
gptkbp:encourages
|
multidisciplinary approaches
|
|
gptkbp:ends_at
|
quality of life assessment
|
|
gptkbp:enhances
|
heart failure pathophysiology
|
|
gptkbp:facilitates
|
patient recruitment
|
|
gptkbp:focuses_on
|
heart failure
|
|
gptkbp:fosters
|
collaboration among researchers
|
|
gptkbp:has_method
|
age 18 and older
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
PROVE-HF study
|
|
gptkbp:impact
|
clinical practice
|
|
gptkbp:includes
|
new insights into heart failure treatment
|
|
gptkbp:influences
|
treatment guidelines
|
|
gptkbp:involves
|
gptkb:sacubitril/valsartan
|
|
gptkbp:is_analyzed_in
|
safety and efficacy
long-term effects
|
|
gptkbp:is_associated_with
|
improved patient outcomes
|
|
gptkbp:is_documented_in
|
gptkb:literary_work
|
|
gptkbp:is_evaluated_by
|
independent reviewers
|
|
gptkbp:is_expected_to
|
future research directions
|
|
gptkbp:is_linked_to
|
guidelines for heart failure treatment
|
|
gptkbp:is_part_of
|
clinical trial registries
clinical research initiatives
heart failure research
|
|
gptkbp:is_related_to
|
heart failure management
|
|
gptkbp:is_studied_in
|
NC T03057977
|
|
gptkbp:is_supported_by
|
medical institutions
|
|
gptkbp:is_utilized_in
|
gptkb:hospital
|
|
gptkbp:launched
|
gptkb:2018
|
|
gptkbp:measures
|
mortality rates
hospitalization rates
|
|
gptkbp:notable_recipients
|
patient education
evidence-based medicine
healthcare innovation
|
|
gptkbp:participants
|
patients with heart failure
|
|
gptkbp:primary_source
|
change in NT-pro BNP levels
|
|
gptkbp:produced_by
|
new hypotheses
|
|
gptkbp:promotes
|
awareness of heart failure
|
|
gptkbp:published_by
|
gptkb:The_New_England_Journal_of_Medicine
|
|
gptkbp:receives_funding_from
|
public and private sources
|
|
gptkbp:registration
|
gptkb:Clinical_Trials.gov
|
|
gptkbp:reports_to
|
medical conferences
|
|
gptkbp:result
|
gptkb:2022
|
|
gptkbp:sponsor
|
gptkb:Novartis
|
|
gptkbp:student_enrollment
|
gptkb:battle
|
|
gptkbp:supports
|
healthcare policy development
|
|
gptkbp:utilizes
|
randomized controlled trial
|
|
gptkbp:vision
|
gptkb:battle
|
|
gptkbp:bfsParent
|
gptkb:Entresto
|
|
gptkbp:bfsLayer
|
4
|